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Abstract:
Mari, Walid. M.S. Department of Pharmacology and Toxicology, Boonshoft School of
Medicine, Wright State University, 2017. Extracellular Microvesicles As a Novel
Biomarker for Wound Healing.

Introduction: Wound healing is a sophisticated dynamic process that involves
complex coordination among a variety of resident cells in a suitable extracellular
environment. Chronic wounds are defined as wounds that fail to heal within a period of 3
months. Negative pressure wound therapy (NPWT) is a closed suction drainage system is
used to enable mass transport of fluid from the body as an adjunct to surgical procedures.
(Oasis-ultra) is a triple layer extracellular matrix containing different types of
glycosaminoglycans (GAGs) like heparin sulfate, hyaluronic acid and chondroitin sulfate.
In addition, it has adhesion molecule such as fibronectin and laminin along with various
growth factors. Extracellular vesicles, (EVs); microvesicles and exosomes are a diverse
family of membrane bound vesicles laden with various proteins, nucleic acids, and lipids
that cells release to the extracellular environment. EVs play a crucial role in cell to cell
communication, as they carry signaling molecules, like lipids, proteins, mRNAs, and
miRNAs. We hypothesize that there is a correlation between the concentration of EMVs
and the percentage of wound healing in treated chronic wounds and the healing
percentage will be enhanced by the combination of Oasis ultra and NPWT. A
prospective, multi-centered, randomized, single-blinded clinical trial that permitted by the
Ethics Committee of the Copernicus was conducted to study whether the combination of
Oasis ultra and NPWT will enhance the healing of chronic wounds when compared with
only NPWT, to measure the concentration of EMVs in the collected wound fluids and
correlate it with the percentage of wound healing and to analyze the extracellular
iii

microvesicles composition to look for growth factors, chemokines and cytokines that play
role in the wound healing

Material and Methods: Wound fluid samples obtained from 14 patients with stage
IV trunk pressure ulcers. The patients were divided in two groups (7 in each group, n=7):
control group on negative pressure wound therapy (NPWT) alone & study group with
NPWT plus Oasis Ultra dressing. NPWT was replaced two times a week, and Oasis
Ultra was applied once weekly for all subjects. Wound size was measured every week
and healing percentage was calculated for the whole 12 weeks of the study. A canister of
NPWT device (wound VAC) was collected from the patients every four weeks of the
study and brought to the lab where a hole was made in the canister by using a drill to
drain the fluids. Protease inhibitor added to the fluid before the fluid stored in a -80°C
freezer. EMVs were isolated using Differential Ultracentrifugation methods, and EMVs
concentration in wound fluid was measured by Nanoparticle Tracking Analysis machine
(Nanosight). EMVs were analyzed for cytokines and growth factors using BioPlex Pro
cytokine assays after determining protein concentration using Bradford assay.

Results: Our data showed that overall healing percentage in the study group after 12
weeks of study was ~ 89% as compared with the control group, which was ~ 52% (P <
0.05). Further, to examine the correlation between EMVs and wound healing percentage,
simple linear regression was conducted using SPSS and Prism pad soft wares. The data
showed that there is a strong positive correlation between EMVs concentrations in wound
fluid and the healing percentage, the R-square was 0.66, and (P ≤ 0.05). The study group
shows high levels of intravesicular concentration of pro-healing cytokines and low levels
pro-inflammatory cytokines; however, control group shows high levels of intravesicular
iv

concentration of pro-inflammatory cytokines and low levels of pro-healing cytokine

Conclusion: Our clinical trial demonstrates that using Oasis-Ultra combined with
NPWT hasten the healing percentage in stage IV pressure ulcers. There is a correlation
between EMVs concentration in wound fluid and the healing percentage of the wound.
EMVs composition could determine the outcomes of the wound healing. The EMVs
particles in wound fluid could serve as a biomarker of the wound healing.
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Introduction:
Wound healing is a dynamic process in which tissue repair itself. Moreover, all
tissues in the human body have the ability of healing, either by regeneration or repair
mechanisms. Regeneration is a process that is simple in concept, i.e., to replace the
damaged tissue with identical cells. On the contrary, repair is the main mechanism by
which injured tissues is replaced by connective tissue, which leads to scar formation [3].
The wound healing process progresses through interactive and overlapping phases, i.e.,
hemostasis, inflammation, proliferation, and remolding. During this process, local cells,
inflammatory mediators, and extracellular matrix actively participate in the four phases of
healing [1]. Furthermore, overlaid on the healing process is a series of precisely
controlled processes corresponding to different cell types in the wound throughout each
specific phase of healing. Tissue damage initiates the healing process that continues as a
series of time-dependent phases: (i) homeostasis and coagulation phase starts
immediately after injury; (ii) inflammatory phase, which starts shortly after that; (iii)
proliferation phase occurs within days of injury; and (iv) remolding phase where the scar
tissue formed and may remain up two years [2]. Immediately after injury, the hemostasis
phase is initiated and is characterized by transient vasoconstriction at the wound site, due
to a temporary neuronal reflex. This transient vasoconstriction decreases or stops the
blood flow in post capillary venules to allow blood cells to marginate from the center of
the blood flow. At this point, the cells are close to the endothelial wall of the blood vessel
and migrate to the site of injury. In addition, hemostatic clotting forms by activation of
the coagulation cascade that is activated by intrinsic and extrinsic pathways leading to
platelet aggregation and formation of a hemostatic plug. This hemostatic plug provides a
1

matrix for invading cells to migrate to the area of injury and start the healing process.
Platelets release cytokines and growth factors to recruit immune cells, endothelial cells
and fibroblast that act to start the process of healing.

Inflammatory phase:
The inflammatory phase starts within hours after the hemostatic phase and lasts
up to 7 days [8]. The inflammatory phase can be subdivided into an early inflammatory
phase and a late inflammatory phase (Velnar et al., 2009). The early inflammatory phase
activates the complement cascade and initiates a series of molecular events causing
infiltration of the wound by leukocytes to fight infection [2]. In the early inflammatory
phase, the endothelial cells upregulate selectin molecules (P selectin, E selectin) that
cause leukocyte rolling over the wall of blood vessels, and cellular adhesion molecules
(ICAM, VCAM) to interact with integrin on the leukocyte leading to firm adhesion of the
leukocyte to the wall of blood vessels [9]. Leukocytes like neutrophils and macrophages
migrate to the site of injury simultaneously, yet the neutrophil comes first due to their
large quantity in the blood [11]. Neutrophils start to be attracted to the wound location
within 24 to 36 hours after injury by a variety of chemo-attractant agents like IL8, C3a,
C5a, bacterial product (formylmethionyl peptides), and platelet product [9]. Leukocytes
migrate to the site of injury using diapedesis, which is a process by which leukocyte
squeeze between the endothelial cells to reach to injury site [2]. Neutrophils fight
bacterial infection by using oxygen-dependent killing through the release reactive oxygen
species (ROS) and release proteases to cleanse wound of cell debris. Once neutrophils
finish their task of removing all bacteria, its activity decreases. Ultimately, before going
to the next stage of healing, the neutrophils must be removed from the wound. The
2

dominant cell in the late inflammatory stage is the macrophage, which arrives at the
wound site 48 to 72 hours after injury. The macrophage is a blood monocyte that undergo
to phenotypic changes upon its arrival to the wound site. Macrophages are attracted to the
wound site by chemokine agents, including C3a, C5a, cytokines like PDGF, TGF-β, and
platelet factor IV, in addition to elastin, and collagen products. Macrophages can work in
low pH and have a longer lifespan than neutrophils [2]. Macrophages are the key
regulator cell that switch the healing process from inflammation to subsequent stages of
healing. Macrophages can release anti-inflammatory cytokines such IL10 and TGF-β to
promote resolution and healing or release pro-inflammatory mediators such as IL8 to
continue acute inflammation by recruiting more neutrophil [9]. The last cells to come to
injury site are lymphocytes, which come to the wound site within 72 hours after the
injury attracted by IL1, Immunoglobulin G (IgG) product, and complement product.

Proliferative phase:
At the end of the inflammatory phase, the proliferative phase begins and
proliferation becomes a dominant process. Proliferation is characterized by reepithelization of the wound bed, angiogenesis to reestablish the wound vascularity, and
granulation tissue formation [14]. Re-epithelialization starts hours to a day after an injury
and involves migration and proliferation of keratinocytes that are derived from epithelial
stem cells of the skin. There are two main populations of the epithelial stem cells in the
skin. First to proliferate are the inter-follicular stem cells that are found in the basal layer
of the inter-follicular epidermis (IFE), and the hair follicle (HF) bulge epithelial stem
cells that are found in the outer root sheath (ORS) of the permanent part of the hair
follicle where the erector Pili muscle insert [15]. These stem cells start their proliferation
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within two to three days of the injury. Afterward, migration is elicited by loss of contact
inhibition and physical pressure at the cellular adhesion molecules (hemi-desmosomes
and desmosomes), which trigger the downstream signal to allow calcium to induce
restructuring of the cytoskeleton for migration. Simultaneously, collagenase and elastase
release keratinocytes from their original locations. When the cell comes into contact with
each other and a new adhesion molecules formed, the migration process stops.
Furthermore, the keratinocytes release protein to rebuild the basement membrane. The reepithelialization process is triggered by many wound-associated signals, e.g., nitric oxide
(NO), which is produced by macrophages during early stages of wound healing [16],
growth factors, including epidermal growth factors (EGF) KGF, IGF-1, and nerve growth
factor (NGF) that are released from multiple cell types in the wounds.
Angiogenesis is a process by which new blood vessel formation is established to
supply the damaged area with critical oxygen and nutrients that are required during
wound healing. Angiogenesis is started by growth factors such as platelet-derived growth
factor (PDGF), vascular endothelial growth factor (VEGF), basic fibroblast growth factor
(bFGF), and the serine protease thrombin. The remaining endothelial cells of the existing
vessels proliferate and migrate toward the angiogenic stimulus. These cells initially form
the lumen of the vessels and then differentiate into venules and arteries and mature by
involving smooth muscles and pericytes. Further, endothelial cells derived from the bone
marrow also form blood vessels de novo [16]. In the proliferative phase, the provisional
matrix made during hemostasis is changed by new granulation tissue. The new
granulation tissue consists of the enormous amount of blood vessels, macrophages,
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granulocytes, fibroblasts, and collagen bundles to retrieve the structure and function and
the injured skin to a certain limit.
The fibroblast is the major role player of the proliferative phase and it plays a
critical role in the process of granulation tissue formation. In response to cytokines and
growth factors like PDGF, transforming growth factor (TGF- ) and bFGF that are
produced by platelets and macrophages, respectively, fibroblasts migrate from the
adjacent dermis to the wound. Furthermore, fibroblasts may also originate from bone
marrow–derived mesenchymal progenitor cells called fibrocytes. These cells circulate in
the blood and migrate to the site of a skin injury to induce healing by secreting cytokines,
growth factors and chemokines, enhance angiogenesis, and serve as antigen presenting
cells. Once in the provisional matrix of the wound, fibroblasts proliferate and secrete
proteases, e.g., matrix metalloproteases (MMPs) to breakdown the provisional matrix and
on the same time deposit collagen and extracellular matrix (ECM) elements like,
hyaluronic acid, glycosaminoglycans, proteoglycans, and fibronectin to form granulation
tissue which seal the wound cavity and serve as a scaffold for cell migration and adhesion
during the wound healing process [16].

Remodeling Phase:
The remodeling process is initiated toward the end of granulation tissue
development. Fibroblasts are induced by mechanical tension and cytokines like TGF-β to
differentiate into myofibroblasts, which contracts the wound through the expression of
smooth muscle actin (SMA). After the wound healing process is accomplished,
myofibroblasts undergo apoptosis. During this phase, collagen type I, which has high
tensile strength, replaces type III collagen in the extracellular matrix (ECM). Finally, the
5

number of newly formed vessels and blood flow decreases, and mature environment that
lack of cells and blood supply is established. Ultimately, Skin appendages like sweat
glands and hair follicles cannot be retrieved after extreme damage; however, the skin can
regain up to 80% of the original tensile strength [16]

Chronic wounds and Pressure Ulcers:
Chronic wounds are defined as wounds that fail to heal within a period of 3
months. Additionally, chronic wounds represent a significant health care problem since
they affect more than 1% of the western population. Chronic wounds also contribute to
an enormous financial burden on the health care system, resulting in annually additional
health care costs of more than $25 billion in the United States [22]. Common chronic
wounds categories are pressure ulcers, diabetic foot ulcers, venous ulcers, and ischemic
ulcers [19]. Per the National Pressure Ulcer Advisory Panel (NPUAP) “a pressure injury
is localized damage to the skin and underlying soft tissue usually over a bony prominence
or related to a medical or another device”. The damage could be presented as unbroken
skin or wide-open ulcer and might be painful. The injury arises due to sever or continued
pressure or combined shear and pressure. Soft tissue may exhibit different tolerance to
pressure and shear and that depends up tissue perfusion, microclimate, nutritional status
of the patients, comorbidities, and the condition of the soft tissue [20].
Pressure ulcers are classified into stages as follows: Stage 1 Pressure ulcer: Nonblanchable erythema of intact skin. Stage 2 Pressure Injury: Partial-thickness skin loss
with exposed dermis. Stage 3 Pressure Injury: Full-thickness skin loss. Stage 4 Pressure
Injury: Full-thickness skin and tissue loss with exposed or directly palpable fascia,
muscle, tendon, ligament, cartilage or bone in the ulcer. Unstageable Pressure Injury:
6

Obscured full-thickness skin and tissue loss. Deep Tissue Pressure Injury: Persistent nonblanchable deep red, maroon or purple discoloration (NPUAP, April 2016) [20]. Pressure
ulcers occur in different body areas include trunk, limbs, and buttocks; however, sacrum
and heel are the most vulnerable areas to pressure since they have a thin layer of soft
tissue and more prone to develop pressure ulcers [18]. These ulcers, as a chronic wound
are thought to be ‘stuck’ in the inflammatory phase of wound healing. The current
concept is that a local increase in the level of proteases like MMPs in the wound bed. The
hypoxic microenvironment breaks down important growth factors and thus prevents the
wound from continuing to the next phase of healing (proliferative phase) to form
granulation tissue and new provisional matrix for remolding and healing [19].

Highly addressed growth factors and interleukins in wound healing:

Complex induction of signals via cytokines, growth factors, and chemokines to
coordinate cellular process is imperative for the successful wound healing process. Those
biologically active polypeptides impact wound healing through affecting target cell
differentiation, metabolism, and growth by paracrine, autocrine, endocrine or juxtacrine
mechanisms. Binding these cytokines with its corresponding receptors stimulate molecular
pathways that regulate cell cycle, motility, and differentiation.
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Table 1: Highly addressed cytokines in wound healing.
Cytokines
Cells
Function

PDGF

FGF-2 or
basic FGF

VEGF

IL-1

Platelets
Macrophages
Endothelial
cells
Keratinocytes
Fibroblasts.
Mast Cells
Keratinocytes
Fibroblasts
Smooth
muscle cells
Chondrocytes
Endothelial
cells
Neutrophils
Platelets
Macrophages
Smooth muscle
cells
Fibroblasts
Endothelial
cells
Monocytes
Macrophages
Neutrophils
Keratinocytes

1. Inflammation
2. formation of
granulation tissue
3. Re-epithelialization
4. Matrix formation
5. Remodeling.
1. Granulation tissue
formation
2. Re-epithelialization
3. Matrix formation
4. Remodeling

formation of granulation
tissue

1. Inflammation
2. Re-epithelialization

IL-6

Monocytes
Macrophages
Neutrophils
Keratinocytes

1. Inflammation
2. Re-epithelialization

TNF-a

Monocytes
Macrophages
Neutrophils
Keratinocytes

1. Inflammation
2. Re-epithelialization

Adapted from Barrientos, 2008 [31].
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Level in
Acute
Wound

Levels in
Chronic
Wounds

Platelet derived growth factor (PDGF):
Platelet Derived growth factor-(PDGF) is one of the growth factors that plays a
crucial role in wound healing, where it enhances cell proliferation, angiogenesis and
chemotaxis response. PDGF is classified based on its structure as a disulfide dimeric
protein comprised of different polypeptide chains (A, B, C, and D). PDGF conveys its
signals through tyrosine kinase receptors, e.g., PDGF-aR or PDGF-bR, and the
downstream extracellular signal kinase (ERK) pathway [21]. It is released from platelets,
fibroblast, endothelial cells, and macrophages. PDGF signaling plays a crucial role in both
cell migration and proliferation. In fact, scientific evidence shows that PDGFR-a signaling
pathway can oversee fibroblast translocation throughout this process. PDGF plays an
important role in each stage of healing. Platelets store PDGF in their alpha granule and
during injury release it in the wound fluid. In the wound, PDGF serves as a strong chemoattractant for both fibroblast, smooth muscle cells, neutrophils and monocytes [31]. PDGF
induces macrophages to release growth factors such as TGF-b, that along with PDGF
enhances macrophage mediated tissue debridement and formation of granulation tissue.
Along with VEGF-A, PDGF-BB is the gene product that regulate hypoxia contribute to
angiogenesis [26]. Moreover, in vitro PDGF shows ability to stimulate formation of new
blood vessels through enhancing VEGF expression synergistically with hypoxia (ischemic
injury). PDGF upregulate the synthesis and production of IGF-1, which has been shown to
induce migration of keratinocytes. PDGF plays a crucial role in re-epithelialization and
thrombospondin-1 that delays proteolytic response and induce proliferative response in
wound healing [31]. Further, PDGF also stimulates fibroblast proliferation and controls
9

collagen production, which are important during the proliferative phase of wound healing
[26]. PDGF stimulate pericyte production of extracellular matrix components such as
collagen, fibronectin, and proteoglycans. PDGF upregulates MMP enzymes and helps to
degrade old collagen which is important during tissue remodeling. PDGF levels is
increased in acute wound and decreased in chronic wound. Indeed, it has been shown that
PDGF levels vulnerable to the chronic wound proteolytic media and its breakdown can be
prevented by MMPs inhibitors [31]. Clearly, PDGF plays a critical role in all phases of
wound healing through stimulating phase specific wound healing cells to communicate and
release their pro-healing cytokines to heal wounds.

Basic fibroblast growth factor (bFGF):
Basic fibroblast growth factor (bFGF) is a member of a family that contains a
structurally related polypeptide found in a diversity of organisms like drosophila,
nematode, mouse and human [32,33]. There are 22 isoforms that comprise the FGF
family in vertebrates. They share 13-71% of their amino acid sequence and have
molecular weights that range from 13 to 17 kDa. Further, FGF1-4 has a strong affinity for
heparan sulfate, which is needed to activate FGF cell surface receptor [34]. FGF produces
a cellular response through binding to a family of four tyrosine kinase receptors which
has an extracellular single transmembrane, ligand binding domain, and a cytoplasmic
domain that contains a tyrosine kinase enzyme and regulatory sequences. The
extracellular ligand binding domain contain immunoglobulin like domains that serves as
a binding site for heparin. [33]. The FGF signaling pathway starts with binding FGF
ligand to FGFRs followed by dimerization process in which a complex of two FGFs, two
heparin sulfate, and two FGFRs formed. Furthermore, each FGF binds to two receptors
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which contact each other by D2 domains to facilitate phosphorylation of each receptor by
tyrosine kinase domain. The best understood FGF downstream signaling pathways are the
phosphoinositide 3 (PI3) kinase/ AKT pathway, RAS/mitogen-activating protein (MAP)
kinase pathway, and phospholipase C gamma (PLCg) pathway. However, the major
downstream pathway is RAS/mitogen-activating protein (MAP) kinase pathway, which is
implicated during cellular differentiation and proliferation [32]. FGFs play a role in
different biological process including cellular embryogenesis, mitogenesis,
differentiation, migration, proliferation, angiogenesis, and wound healing [32]. The bFGF
plays a crucial role in wound healing. In fact, bFGF is a positive regulator and strong
inducer of angiogenesis since it recruits inflammatory cells like neutrophils, monocytes,
and macrophages, increase expression of different chemokines like CXCL1 and
chemokine 2 and 7, and induces endothelial cells mitogenesis [36]. It also plays a critical
role in re-epithelialization, formation of granulation tissue and tissue remodeling.
Previous in vitro studies have shown that bFGF controls ECM deposition, increases
migration of keratinocytes during re-epithelialization, and enhances fibroblast migration
and trigger it to release collagenase. Previous in vitro studies have also shown that FGF
7-10 (keratinocyte growth factor) can induce keratinocyte proliferation and migration that
is critical in re-epithelialization and that they participated in the detoxification process of
reactive oxygen species (ROS). In acute wounds bFGF levels increase, yet their levels are
decreased in chronic wounds. Further, clinical studies using FGF to treat pressure ulcers
showed a trend toward earlier wound closure [31]. In conclusion, bFGF is a member of
family that structurally related polypeptide found in variety of organisms including
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human. The bFGF play important role in wound healing processes including angiogenesis
with granulation tissue formation, re-epithelialization, and tissue remodeling.

Vascular Endothelial Growth Factor (VEGF):
Also, known as vascular permeability factor is a homodimeric glycoprotein that stimulate
endothelial cell migration, proliferation and survival. In addition, VEGF has inflammatory
properties through it is ability to induce microvascular permeability and leukocyte adhesion
[30]. VEGF has five isoforms which resulted from alternative splicing of its mRNA, and
are generally denoted as VEGF-A, VEGF-B, VEGF-C which secreted from macrophage,
VEGF-D and placental growth factor (PIGF) [29]. The chain length changes VEGF from
weakly acidic to a basic form, which increases the capability of the molecule to bind to
heparin. The shorter variant is the main isoform which is soluble in extracellular space.
VEGF is released from different kind of cells that contribute in wound healing: fibroblast,
endothelial cells, smooth muscle cells, platelets, macrophage, and neutrophil. VEGF binds
to receptors that are members of type III tyrosine kinase family, that contain seven
immunoglobulin-like extracellular domains, a single transmembrane spanning domain, and
intracellular tyrosine kinase domain. Both KDR and Flt-1receptors found on the
endothelial surface of mature and immature blood vessels. KDR receptor mediate
chemotactic and mitogenic activity of VEGF and proliferation, chemotaxis, and membrane
ruffling in KDR expressing endothelial cells. However, Flt-1 receptor mediate vascular
permeability and chemotactic response of macrophage and neutrophil [29]. Stimulation of
angiogenesis is one of the roles that VEGF plays in the process of wound healing.
Angiogenesis includes vasodilatation, basement membrane breakdown, and endothelial
cell proliferation and migration. The levels of VEGF-A along with VEGFR are elevated in
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acute wounds. Indeed, upon acute injury platelets secrete VEGF-A. Moreover, during
wound healing process, macrophages release TNF which increase the expression of
VEGF-A in fibroblasts and keratinocytes. Furthermore, hypoxia is the main trigger for
VEGF-A release in acute wound that results in angiogenesis to reestablish microcirculation
to maintain tissue perfusion. In fact, hypoxia induce expression of VEGF in Fibroblasts,
monocytes, keratinocytes, endothelial cells, and myocytes [31]. To sum up, VEGF is an
important growth factor that promote wound healing through promoting angiogenesis to
form granulation tissue.

Pro-inflammatory cytokines and chemokines:
Pro-inflammatory cytokines and chemokines are important players in the wound healing
process. After injury, a huge number of cytokines including specifically Interleukin-1 (IL1), Interleukin-6 (IL6), and Tumor necrotic factor alpha (TNF) induce inflammation and
are released from different inflammatory cells [37]. These cytokines are upregulated during
inflammatory phase of wound healing. IL-1 is secreted by neutrophils, macrophages,
monocytes, and keratinocytes. In wound healing keratinocytes produce IL-1 immediately
and along with its action on target cells IL-1 also enhances keratinocytes migration and
proliferation. It has been shown that IL-1 upregulates the expression of K6 and K16 in
migrating keratinocyte [31]. In addition, IL-1 also stimulates fibroblast to release of FGF7[37]. IL-6 is released by neutrophils and monocytes and has been shown to play role in
starting healing response. Its levels increase in acute wounds and remain high in chronic
wounds. It is a neutrophil chemoattractant and induces keratinocytes proliferation and
mitogenesis. TNF is produced by monocytes, macrophages, neutrophils, keratinocytes
and can enhance the synthesis of FGF7, proposing potential its implication in promoting
13

re-epithelialization indirectly. Further, Exogenous TNF has time and concentration
dependent effect on the wound healing indicating that balancing pro-inflammatory signals
regulating wound healing. At low concentration TNF can promote healing through
triggering inflammation and inducing macrophage to release growth factors. In contrast, at
high concentration particularly for prolonged time TNF can negatively affect wound
healing. At high levels, TNF increases the production of MMPs (MMP-1, MMP-2, MMP3, MMP-9MMP-13, and MT1-MMP) and suppresses the production of ECM proteins and
tissue inhibitor metalloproteinases (TIMPs). TNF has been shown to increase the level of
tissue collagenase, stromelysins, and gelatinase which their levels is elevated in chronic
non-healed wounds. Chemokines are another contributor in wound healing, which induces
migration of multiple cells to the wound site. Further, chemokines receptors (CXC
receptors) on resident cells suggests that these chemokines participate in controlling of
angiogenesis, re-epithelialization, and tissue remodeling. Macrophage chemoattractant
protein (MCP1) is one of CC family ligands that works by binding to CXC receptors (G
couple receptors). Its expression is upregulated in keratinocyte during wound healing. It is
a chemoattractant for monocytes, macrophages, mast cells, and T cells. Persistent
expression of MCP-1 in chronic wounds lead to prolonged recruitment of neutrophils and
macrophages which lead to sustained inflammatory phase. Hence, chronic wounds stuck
in inflammatory phase and do not heal.

Extracellular Microvesicles:
Extracellular vesicles, (EVs); microvesicles and exosomes are a diverse family of
membrane bound vesicles laden with various protein, nucleic acids, and lipids that cells
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release to the extracellular environment [12]. In 1967, Wolf observed EVs in the
extracellular space [13]. In 1983, Pan and Johnstone described EVs as part of the
disposal mechanism to get rid of the wasted materials from the cells [12]. Recently, the
International Society for Extracellular Vesicles has suggested calling all types of vesicles
that found in the extracellular space by the term of extracellular microvesicles (EVs).
EVs are particles that varies in size 20nm- 2mm surrounded by phospholipid bilayer
membrane and shed to the extracellular space through a specific release and formation
mechanisms. EVs release and content depend on which cell they originated from and the
stimulus of release, e.g., exposure to lipopolysaccharide (LPS), hypoxia, oxidative injury,
exposure to shear force stress [23]. MVs formation is initiated from outward budding of
cytoplasmic protrusions, then detached from the cell surface. This process is dependent
on calcium influx, and cytoskeleton reorganization. The MVs release ensues in all cells in
resting state or up on activation by physical or chemical stress like hypoxia, oxidative
stress, or shear stress or soluble agonists [24]. Furthermore, MVs hold the signature of
the cellular origin and function as a cargo for transporting cellular content to other cells,
in which they induce change in the phenotype and behavior of the cells [23]. There are
three different groups of EVs have been defined based on their physical features and
mechanism of formation: 1- microvesicles (MVs), 2- exosomes, 3- apoptotic bodies.
MVs sizes range between 100-1000nm, its density is 1.04-1.07 cell surface (g/ml), the
mechanism of formation is by outward cell membrane blebbing, and composed RNA,
miRNA, other non-coding RNA, cytoplasmic protein, and cell organelles. Further, its
membrane is not permeable (PI negative), and cell surface markers are Annexin V
positivity, Origin cell-specific markers. Moreover, there is no single unique marker to
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recognize each group of EVs including MVs; however, there are proteins that have been
used as markers and not specific to each EVs group. Those surface markers include,
major histocompatibility complex (MHC) molecules, heat shock proteins; HSPs, Tsg101,
tetraspanins like CD9, CD63, CD81 and CD82; 14-3-3 proteins, and the Endosomal
Sorting Complex Required for Transport (ESCRT-3) binding protein Alix [27]. MVs can
be characterized by using high sensitivity flow cytometry and imaging flow cytometer as
small as 100 nm in diameter. However, a flow cytometer is unable to characterize smaller
sizes like exosomes. Innovative instruments like dynamic light scattering and
nanoparticle tracking analysis have shown ability to determine and characterize EVs with
diameter smaller than 100 nm [23]. Various mechanisms whereby MVs stimulate the
cells including direct interaction with cells by receptors and molecules are expressed on
their surfaces that bind with ligands expressed on the recipient cells. After interacting
with ligands, MVs could transport their content to the receiver cells [24]. Extracellular
vesicles play a critical role in cell to cell communication, as they carry signaling
molecules, like lipids, proteins, mRNAs, and miRNAs. In 1980, Poste et al. first show
that plasma membrane vesicles from highly metastatic B16 cell line transfer plasma
membrane content to a poorly metastatic B16 cell line, that increased its metastatic ability
(Poste and Nicolson, 1980). In 1998, Zitvogel et al reported that dendritic cells derived
EVs (exosomes) stimulate T-cell antitumor response in vivo (Zitvogel et al, 1998). In
2010, Camussi et al., showed that human liver stem cells derived microvesicles induce in
vitro proliferation and apoptosis resistance in human and rat hepatocytes and in vivo
MVs hasten the functional and morphological recovery of the liver in a model of 70 %
hepatectomy in rats [24]. In 2012, Camussi et al., also showed administration of a single
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dose of endothelial progenitor cells derived microvesicles (EPC- MVs) instantly after
renal ischemia and reperfusion injury in rats was able to produce morphological and
functional protection from acute kidney injury through inducing proliferation and
reducing apoptosis of renal tubular cells [24]. In addition, EPC-MVs showed the ability
to protect against chronic kidney disease by blocking glomerulosclerosis, capillary
rarefaction, and tubule-interstitial fibrosis. Depletion of miRNA content in MVs
decreased the renal protecting result of EPCs [24]. Further, EPC-MVs also decreased
damage and improved reperfusion in murine model of hind limb ischemia. He et al.
recently showed that MSc- derived MVs protect against renal injury in the mouse
remnant kidney model (5/6 subtotal nephrectomy). In this model, single administration of
MVs preserved the function of leftover kidney [24]. Reis et al. also reported that purified
MVs reduce gentamicin induced acute kidney injury. When MVs incubated with RNase,
the in vivo effects were reduced, indicating that the protective effects are mediated by
RNAs that conveyed by MVs [24]. Ultimately, EVs are no longer considered as “cell
dust”, yet as efficient messengers in intercellular signaling, impacting both adjacent and
distant cells (Camussi et al., 2010a; Loyer et al., 2014) [23].

Negative Pressure Wound Therapy:
Closed suction drainage system is used to enable mass transport of fluid from the
body as adjunct to surgical procedures. For instance, a chest tube using this system to
evacuate air from the pleural cavity. Moreover, closed suction is also used to drain stomach
content, which facilitate small intestinal obstruction treatment. High suction can remove
even tissue from the body like in liposuction. In 1990s, Argenta and Morykwas faced a
huge number of complicated wounds, and they tried to come up with a better approach to
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treat these complex wounds. The first idea was to develop a way to apply suction on the
wound to pull the wound edges together; based on this idea, they designed several
prototypes that expedited wound healing. The prototype that has had significant success
in treating wounds was the one that has open pore polyethylene foam that positioned in the
wound, shielded by semi-adhesive dressing, and linked by tube to a suction source. They
named this technique as negative pressure wound therapy (NPWT).

Alternative

description that is more precisely define the physics of the method is micro-deformational
wound therapy (MDWT).

Argenta and Morykwas device has changed the course of

treatment of many patients with complex wounds now a day, and has become the standard
of care that used to heal these kinds of wounds in the USA. According to Orgill et al.
(Orgill & Bayer, 2013, p.17) NPWT mechanisms of action divided into primary and
secondary effects that affect the process of wound healing. The primary effects include
tissue macro-deformation in which the wound edges pulled together by the open pore foam;
however, that effect depends on the mobility of tissue surrounds the wound. Furthermore,
microscopic deformation at the wound surface stretches the cells enhances cell
proliferation and division [5]. In addition, NPWT can eliminate large amount of
extracellular fluid and afford an isolated suitable moist environment to the wound to heal.
The secondary effect includes promoting granulation tissue via up regulation of HIF1alpha-VEGF pathway through micro-deformation effect, which promotes localized
hypoxia close to the wound surface [4]. In addition to that, NPWT modulate inflammation,
induce cellular proliferation, and change the bacterial levels in the wound.

NPWT

indicated for various type of wounds include acute, subacute, chronic, Traumatic, or
dehisced wounds. NPWT also indicated for partial-thickness burns, ulcers like diabetic,
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pressure or venous insufficiency ulcers, and flaps and grafts. NPWT is contraindicated in
malignancy (since proliferation is induced by NPWT may enhance malignant growth),
untreated osteomyelitis, non-enteric and unexplored fistulas, necrotic tissue with eschar,
sensitivity to silver (GranuFoam Silver dressing only) [4].

Oasis Ultra:
Collagen is the most abundant protein in the human body, and it is a fundamental
component in the extracellular matrix. Collagen is an obligatory protein in all stages of
wound healing cascade. Fibroblast secrete collagen in the proliferative phase of wound
healing to direct keratinocyte migration to the areas that need substitution of the injured
epidermis. Collage-rich dressing is a dressing that induces the production and
organization of collagen. Furthermore, it also helps in making an appropriate
environment to enhance healing through recruiting cells like fibroblast and macrophage.
In addition, this type of dressing is convenient in application, removal, and provide an
absorptive moisture environment to promote healing. Collagen-rich biomaterial is often
synthesized from avian, bovine, and porcine collagen. This kind of dressing made from
oxidized regenerated cellulose plus plant based biomaterial to produce a dressing that
inactivate the metalloprotease to prevent destruction of the provisional extracellular
matrix [6]. Oasis-ultra is a triple layer extracellular matrix containing different types of
glycosaminoglycans (GAGs) like heparin sulfate, hyaluronic acid and chondroitin sulfate.
In addition, it has adhesion molecule such as fibronectin and laminin along with various
growth factors like transforming growth factor (TGF-b), basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) [7]. Oasis Ultra composition
stimulates cell migration, reduces inflammation, provides moisture to the wound bed,
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structural support, and enhance cellular proliferation and attachments. Oasis Ultra used
for variety of wounds including chronic vascular ulcer, partial thickness burn, donor site,
diabetic ulcer, preparation for skin graft, venous ulcer, partial and full thickness wound,
surgical wound, traumatic wound, venous ulcer, and wound dressing [6].

Hypothesis:
We hypothesize that there is a correlation between the concentration of EMVs and the
percentage of wound healing in treated chronic wounds and the healing percentage will
be enhanced by the combination of Oasis ultra and NPWT.

Specific Aims:
1. To see whether the combination of Oasis ultra and NPWT will enhance the
healing of chronic wounds when compared with only NPWT.
2. To measure the concentration of EMVs in the collected wound fluids and
correlate it with the percentage of wound healing.
3. To analyze the extracellular microvesicles composition to look for growth factors,
chemokines and cytokines that play role in the wound healing.

Material and Methods:
Experimental design:
The study was a prospective, multi-centered, randomized, single-blinded clinical
trial that permitted by the Ethics Committee of the Copernicus. Written informed consent
was attained from all patients. We discussed and answered patients’ concerns before
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obtaining the consent. Wound fluid samples obtained from 14 patients with stage IV
trunk pressure ulcers. The patients were divided in two groups (7 in each group, n=7):
control group on negative pressure wound therapy (NPWT) alone & study group with
NPWT plus Oasis Ultra dressing. Further, NPWT was replaced two times a week, and
Oasis Ultra was applied once weekly for all subjects. Wound size was measured every
week for the whole 12 weeks of study.

Subject Selection:
Potential candidates evaluated by the study principal investigator for
Inclusion/Exclusion criteria. Most the subjects enrolled at Sycamore Medical Center’s
Wound Center, yet subjects also enrolled at other participating sites.

Inclusion criteria for this study include:
1. Adults aged 18-89 who exhibit stage III or IV trunk pressure wounds with no signs of
infection.
2. HbA1C < 8 (if patient is diabetic)
3. Adequate nutrition including albumin ≥ 2.0 and pre-albumin ≥ 12.5.

Exclusion criteria for this study include:
1. Wounds that cannot have a NPWT device properly applied due to location (too close to
anus), diarrhea, peri-wound skin issues.
2. Patients with Infected wounds.
3. Patients with HbA1C >8, uncontrolled diabetes.
4. Malnourished patients.
5. Patients that are immunodeficient or immunocompromised.
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6. Patients that have a religious or ethical aversion to porcine products.
7. Patients that have any allergy to porcine products.
8. Patients who are at High Risk of bleeding including:
a. Patients who have weakened or friable blood vessels or organs in or around the
b. wound as result of, but not limited to:
c. Suturing of the blood vessel (native anastomoses or grafts) / organ
d. Infection
e. Trauma
f. Radiation
g. Patients without adequate wound hemostasis
h. Patients who have been administered anticoagulants or platelet aggregation
inhibitors
i.

Patients who do not have adequate tissue coverage over vascular structures

9. Patients who are do not resuscitate and/or do not intubate (DNR/DNI).
The patient’s medical record will be referenced for all Inclusion and Exclusion criteria.
Lab results for albumin and prealbumin up to 30 days prior to enrollment and HbA1C
results up to100 days prior to enrollment will be considered in determining eligibility.
At approximately months 1, 2, and 3, wound specimen canisters will be collected
and taken to the laboratory at Wright State University (WSU) department of Pharmacology
and Toxicology for analysis of the drained fluids from all wounds. Specimen canisters will
be secured in biohazard bags and transported to WSU by a member of the study team within
24 hours of collection.
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For all wounds, fluid samples, canisters fluids will be obtained in a sterile fashion.
Part of the fluid will be used for the study and the other part will be stored in liquid
nitrogen at- 80C for potential later use, possibly unrelated to this study. If a subject refuse
to allow their samples to be used outside of this study, that subject’s extra fluid sample
will be destroyed.
To maintain blinding for the assessment lab personnel, specimen canisters and
stored specimens will be identified by a coded label. Pressure reduction beds and patient
repositioning will be employed throughout the study as a standard of care for those
patients.
Table 2: Demography of the patients who joined the clinical trial
Variable
Total number
Males
Female
Wound location
Smoking

control
7
3
5
6 Sacrum, 1 left ischium
None

study
7
4
2
sacrum
None

Sample preparation:
A canister of NPWT device (wound VAC) was collected from the patients every four
weeks of the study and brought to the lab where a hole was made in the canister by using
a drill to drain the fluids. The wound fluid was pull out from the canisters and
aliquoted to 1.5 ml eppendorph tubes. Protease inhibitor added to the fluid before the
fluid stored in a -80°C freezer.

Microvesicles isolation:
Microvesicles were isolated using Differential Ultracentrifugation method.
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1. Patients sample mixed in 5 ml of 20 nm filtered (Whatman, Pittsburgh, PA)
phosphate-buffered saline (PBS).
2. Samples transferred to a centrifuge tubes, 5 ml of Filtered PBS added to dilute the
samples.
3. The wound fluid samples are centrifuged at 4 °C (500 × g for 10 min followed by
2,000 × g for 20 min) to remove intact cells and cell debris. New tubes used after
every centrifugation stage.
4. The supernatant centrifuged at 10,000-× g for 2 hours to isolate MVs.
5. MVs pallets suspended in 1 ml of filtered PBS.
6. Take 5 microliter from the sample and dilute it in 695 µl Filtered PBS for analysis
by using Nanoparticle Tracking Analysis machine (Nanosight).
7. Microvesicles concentration measured by Nanoparticle Tracking Analysis
machine (Nanosight).

Nanoparticle tracking analysis (NTA):
Purified MVs samples were analyzed by NTA using NanoSight (NS300) with a
405-nm laser instrument (Malvern Instruments, United Kingdom). 5 microliters from the
samples were diluted in 695 µl Filtered PBS and three 30 second videos were recorded
using camera level 12–15 with frame rate 30 frame per second. The data was analyzed
using NTA software 3.0 software (Malvern Instruments) which was optimized to first
identify and then track each particle on a frame-by-frame basis [35]. The detection
threshold optimized for each sample and screen gain at 10 to track as many particles as
possible with minimal background [10].
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Cytokine Analysis:
BioPlex Pro cytokine assays are multiplex immunoassays similar to sandwich
ELISA assays that differ by using magnetic beads to couple a biomarker of interest. The
antibodies are covalently linked to magnetic beads and bind to the biomarker of interest
when exposed to the sample. The magnetic bead-cytokine complex washed repeatedly to
remove excess protein and a detection antibody added that bound to the primary
antibody, thus completing the sandwich complex. Streptavidin-phycoerythrin conjugate
served as a fluorescent indicator.
1-The 96 wells plate from the Human Cytokine 27Plex kit was first ‘wetted’ with Assay
buffer.
2-the beads solution was added to the respective wells and washed twice with wash
buffer.
3- Samples and controls (50

l @ ~ 3-10

g/ l) were loaded into individual wells and

analyzed in duplicate.
4- An aliquot of each sample assayed for protein content by the Bio-Rad method.
5- The plate was kept for incubation followed by 3 washes with buffer.
6- A detection antibody added to each of the wells for 30 minutes incubation at room
temperature.
7- Streptavidin-phycoerythrin conjugate added to each of the wells and washed 3 times
with wash buffer.
8- By using Bioplex 200 instrument the plate scanned at both a low PMT (normal) and
high PMT, and statistics computed using suitable software and analyses.
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Statistical analyses:
Analyses performed using Graph Pad Prism 7, Excel 2016, and SPSS version 13
software. Statistical comparisons were expressed as mean ± SEM for continuous
variables of experiments conducted at least three times, where n is the human subject.
The differences between the groups were done by multiple comparison and analyzed by
ANOVA, Paired or non-Paired t test. Simple linear regression employed to study the
correlation between the healing percentage and EMVs concentration. In all cases, P ≤
0.05 was considered statistically significant.
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Results:
The total number of patients involved in the study during the period between
August 2014 and June of 2016 was 94 patients. Thirty-nine subjects were consented,
nineteen were withdrawn from the study for different reasons that the primary
investigator determined and seventeen subjects finished the study successfully.

The effect of Oasis ultra on the healing percentage in both groups
The healing rate was studied over a 12week period with every week’s measurement
recorded. The wounds that received the standard of care (NPWT, wound VAC) only,
showed an increase in the healing rate at the beginning of the study with a peak at 8
weeks, after which the healing rate declined for the rest of the study period (Figure 1).
The healing rate of the wounds that received Oasis ultra in addition to the standard of
care (NPWT, wound VAC) showed a steady increase over time until the end of the study
period (Figure 1).
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Figure 1: Percent Healing versus Time. Healing percentage calculated for every
week by comparing wound volume of the current week with the previous week of the study.
The difference in healing between the two groups was analyzed by one-way
ANOVA, (Table 1). The difference was significant at p< 0.05. Using these results a Box
and Whisker Plot was performed to show the average of overall healing percentage after
12 weeks in both groups (Figure 2).

Table 3: Average healing percentage after 12 weeks of study both groups.
Dependent variable: Healing percentage
Groups

Mean

Std. Deviation

N

Control

52.3271

35.82278

7

Study

88.8386

9.741854

7

ANOVA: single factor
Control vs study groups: F= 6.77, df (1, 12), (P ≤ 0.05).
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Figure 2: Average Percent Healing in the Control and Study groups. The box and whisker plot
shows the difference in healing between the two groups.

The average healing percentage in the 2 groups at four, eight and twelve weeks
was compared using one-way ANOVA. There was no significant difference in the
healing percentage between the two groups at four-weeks, p = 0.29; eight-weeks p =
0.41. However, at twelve-weeks there was a significant difference between the two
groups p< 0.05. Both group’s healing percentage increased over time with the peak at 8
weeks. In the 12th week, the wounds treated with Oasis Ultra continued to show an
increase in healing, while the wounds treated with the standard of care (NPWT) did not.
These findings suggest that Oasis Ultra may be facilitating the progression through
wound healing stages.
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Figure 3: Overall healing percentage (H%) in both study and control groups
at 4, 8, and 12 weeks.
The difference in healing percentage between the two-time points in the (4
weeks,12 weeks) study group was performed by Paired t test, (Table 3). The difference
was significant, p<0.05. Using these results, a Box and Whisker Plot was performed to
show the average healing percentage at 4 and 12 weeks in the study group (Figure 4).
However, the difference in the average healing percentage between 4 and 12 weeks’ time
points was not significant (P = 0.07). Using this result, Box and Wesker Plot was performed
to show the average of healing percentage at 4 and 12 weeks in study group (Figure 4).

Table 4: Average healing percentage at 4 and 12 weeks of study in study group
Dependent variable: Healing percentage
Study Group
Mean of differences SD of differences
Number of pairs
4, 12 weeks
-35.9

18.92

Paired t test
4 weeks, vs 12 weeks: t, df, t=5.022 df=6, (P ≤ 0.05).
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Figure 4: Average healing percentage. between 4 and 12 weeks’ time point of the
study group (P ≤ 0.05).

Extracellular Microvesicles Correlation with Percent Healing
One of the goals of this project was to determine if microvesicles concentration
would correlate with the percent healing or healing rate of wounds. To study this, we
examine the number of Extracellular Microvesicles (EMVs) in the wound exudate at the
different time points. This data was then compared with wound size of each patient and
are presented as the Control group and Study group for clarity (Figure 5 & 6). Patients in
the control group appeared to have less MVs concentration and relatively smaller size
wounds in comparison with the study group patients who had larger wounds and more
MVs. The assignment of each patient to the group was randomized, even though the
wound sizes were more tightly grouped than would be thought by random selection.
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Figure 5: Control EMVs conc. at 4, 8, and 12 weeks. Each dot represents data of
one patient.
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Figure 6: EMVs conc. vs Wound size in the study group at 4, 8, and 12 weeks .
Each dot represents data of one patient.
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To analyze this, further, the MVs concentration (EMVs conc. x 108 Particle/ml) was
plotted against Percent Healing and the data for each time point analyzed by ‘connecting
the dots’ and color coding (Figure 7A & B). From these plots, we determined that there
was a higher EMV concentration that correlated with higher percent healing in the wounds
treated with the combination of Oasis Ultra dressing and NPWT, as compared with the
wounds that were treated with NPWT alone. These findings suggest that Oasis Ultra may
provide an environment conducive to increased EMVs concentration.

Figure 7 A & B: EMVs conc. vs Wound Healing percentage in the control and
study groups at 4, 8, and 12 weeks. Each dot represents data of one patient.

To test if EMVs concentration in wound fluid could impact wound healing
percentage regardless of the wound treatment, a simple linear regression was conducted
to see if EMVs concentration could be a predictor for the healing percentage (Table 4).
We observed that regardless of which treatment the patients get, there is positive
correlation between EMVs concentration in wound fluid and healing percentage. In
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another way, there is increase in healing percentage for every single unit change in the
EMVs concentration (Figure 8). These finding also suggests that EMVs concentration in
wound fluid could predict the healing rate and potentially could serve as biological
biomarker for wound healing.

Table 5: the effect of EMVs Con. On H% treatment
Standardized coefficient, Beta

R square

Number of
patients

0.81

0.66

12

Simple Linear Regression
All patients: F, (df, df) = 69.42, df =1,35 (P = 0.00)
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Figure 8: Analysis of Percent Healing versus EMV Concentration. Linear
regression using SPSS Statistical Software version 13 was conducted to analyze the data
of all patients regardless the treatment, and data showed that there is a positive correlation
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between MVs concentration and wound-healing percentage, the R-square was 0.66, and (P
≤ 0.05).

Extracellular Microvesicles (EMVs) Composition Analysis :
Based on the results so far, we analyzed the EMVs for the presence of cytokines,
chemokines and growth factors using a Bio-Rad BioPlex (Luminex) instrument to run the
27 Bio-Plex ProTM Human Cytokine, Chemokine, and Growth Factors Assay (Table 5).
All data was presented as mean ± SEM. All cytokine concentrations were normalized to

total protein concentrations that were measured by Bio-Rad (Bradford) protein assay.

Table 6: EMVs Cytokines analyzed by 27 Bio-Plex Pro Human Cytokine,
Chemokine, and Growth Factors.
IL-1

IL-10

IL9

G-CSF

IL-6

PDGF

IL13

MIP-1α

IL-8

VEGF

IL15

MIP-1β

IL-12

bFGF

IL17

G-CSF

TNF-α

IL-1 Ra

IL2

GM-CSF

INF-

IL-4

Eotaxin

IP-10

IL-5

GM-CSF

MCP1(MCAF)

IL7

RANTES
(CCL5)

In our study, we found that the wound fluid concentration of EMVs was different
among the two groups and the composition of cytokines in or on these vesicles was also
different. We observed that the concentration of PDGF, bFGF, and VEGF in EMVs
isolated from the wounds treated with the combination of Oasis ultra and NPWT
appeared to increase during 4 weeks and to decrease gradually in the 8th and 12th week
(Figure 12, 13, 14). However, from a statistical standpoint, there was no significant
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difference within the groups at 4,8, and 12 weeks of the study, most probably due to the
small sample size. Overall, the wounds who treated with NPWT alone appeared to show
smaller concentration of these intravesicular growth factors at 4, 8, and 12 weeks
compared with the wounds that received combined therapy of oasis ultra and NPWT.
Further analysis with larger N is necessary to show significant differences in these
growth factors.
There also appeared to be an increase in intravesicular IL-1

and IL-1RA

antagonist levels in study group at 4, 8, 12 weeks compared with control group (Figure
12 & 13), although again, the data was not significant.
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Figure 9: Intra-vesicular concentration of platelet derived growth factor PDGF
(Pg/ml). At 4 week and decrease gradually at 8, and 12 weeks of the study group. However,
in the control group, its concentration is small in all weeks of study. Statistical comparisons
were expressed as mean ± SEM for continuous variables of experiments conducted, where n
is the human subject.
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Figure 10: Intra-vesicular concentration of Fibroblast growth factor bFGF (pg/ml)
at 4 week and decrease gradually at 8, and 12 weeks of the study group. However, in the
control group, its concentration is small in all weeks of study. Statistical comparisons were
expressed as mean ± SEM for continuous variables of experiments conducted, where n is the
human subject.
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Figure 11: Intra-vesicular concentration of Vascular Endothelial Growth
Factor(VEGF) (Pg/ml) at 4 week and decrease gradually at 8, and 12 weeks of the study group.
However, in the control group, its concentration is small in all weeks of study. Statistical
comparisons were expressed as mean ± SEM for continuous variables of experiments conducted,
where n is the human subject.
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conducted at least three times, where n is the human subject
Statistical comparisons were expressed as mean ± SEM for continuous variables of
experiments conducted at least three times, where n is the human subject
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Figure 12: Intra-vesicular concentration of interleukin 1receptor anta gonist IL -1Ra
(Pg/ ml). Vs time at 4, 8, and 12 weeks of the study both groups. Statistical

comparisons were expressed as mean ± SEM for continuous variabl es of experiments
conducted, where n is the human subject.
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Figure 13: shows the intra-vesicular concentration of interleukin-1 beta IL-1
(Pg/ml) Vs time at 4, 8, and 12 weeks of the study both groups. Statistical comparisons were
expressed as mean ± SEM for continuous variables of experiments conducted, where n is the
human subject.
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The intravesicular concentration of pro-inflammatory cytokines, i.e., IL-6, TNF,
IL-8, IL-12, INF-Ɣ, MCP, and IP10 appeared to increase at 4 weeks and remain elevated
at 8 and 12 weeks in the control group as compared with study group (Figures 14-18).
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Figure 14: Intra-vesicular concentration of interleukin 6 IL -6 (Pg/ml) Vs time at 4, 8,
and 12 weeks of the study both groups. Statistical comparisons were expressed as mean ± SEM
for continuous variables of experiments conducted, where n is the human subject.
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Figure 15: Intra-vesicular concentration of interleukin 8 IL-8 (Pg/ml) Vs time at 4,
8, and 12 weeks of the study both groups. Statistical comparisons were expressed as mean ±
SEM for continuous variables of experiments conducted, where n is the human subject.
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Figure 16: Intra-vesicular concentration of interleukin 12 IL-12 (Pg/ml) Vs time at
4, 8, and 12 weeks of the study both groups. Statistical comparisons were expressed as mean
± SEM for continuous variables of experiments conducted, where n is the human subject.
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Figure 17: Intra-vesicular concentration of tumor necrotic factor alpha TNF -
(Pg/ml) Vs time at 4, 8, and 12 weeks of the study both groups. Statistical comparisons were
expressed as mean ± SEM for continuous variables of experiments conducted, where n is the
human subject.
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Figure 18 A & B: Intra-vesicular concentration of interferon gamma INF -Ɣ
(Pg/ml) Vs time at 4, 8, and 12 weeks of the study in both groups. Statistical comparisons
were expressed as mean ± SEM for continuous variables of experiments conducted, where
n is the human subject.
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Discussion and Conclusion:
Wound healing is a sophisticated dynamic process that involves complex
coordination among a variety of resident cells in a suitable extracellular environment
[39]. The wound healing process is initiated by tightly coordinated, interactive, and
overlapping time-dependent stages. These stages include hemostatic, inflammatory,
proliferative, and remodeling phases wherein resident cells, inflammatory mediators, and
extracellular matrix actively participate in each phase of healing [1,3]. Highly
coordinated signals through cytokines, growth factors, and chemokines are required for
fruitful wound healing process. Those cytokines binding to their corresponding receptors
and exert their actions through endocrine, autocrine or paracrine mechanism through
triggering specific molecular cascade that yield a change in target cells metabolism,
growth, and differentiation [31]. The goal of this project was to attempt to identify
specific factors that could either influence wound healing, or act as an indicator of the
wound healing process, both positively or negatively.
Our main objective of this project was to determine if wound healing could be
enhanced by addition of a type of dressing, the Oasis Ultra, in conjunction with NPWT
which was being used as the standard of treatment. The results clearly show that the
Oasis Ultra did in fact significantly enhance wound healing, as measured by healing rate
or average wound size. This is a substantial finding considering that the average size of
the wounds in the Study group was significantly larger than the size of the wounds in the
Control group. No other study has been conducted to compare the use of Oasis Ultra in
combination with NPWT with wound NPWT alone. Thus, our results would suggest a
positive shift in the treatment for large wounds such as these.
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A second goal of the project was to determine if microvesicles were in higher
abundance in the Oasis Ultra Study Group than in the wound NPWT Control group.
Microvesicles are being identified in numerous studies as both an indicator of risk as well
as having the ability to enhance or positively influence wound healing. We showed that
the overall concentration of microvesicles increased over time in the wounds treated with
Oasis Ultra versus NPWT alone. The results also showed an increased healing rate
concomitant with an increased microvesicles concentration regardless of the treatment,
but that it appeared to be increased with Oasis Ultra. The small sample size of this study
made significance difficult for most of these assays.
The third goal of the project was to ascertain if the microvesicles contained
specific cytokines, chemokines, or growth factors. This has not been determined
previously, but would suggest that if they did, there would be a potential for some type of
communication between the cytokine, chemokine, or growth factor and cells in the
wound site itself. Cellular communication between cells is crucial during the healing
process. Although cells communicate mainly through secretion of different kinds of
proteins that bind to specific receptors on adjacent cells; the mode of intercellular
communication via EMVs has been suggested to play a critical role in healing [40].
In our present study, we observed intravesicular cytokines and growth factors
concentration attached to or inside the microvesicles. This would strongly suggest that
there could be signaling events initiated by these types of proteins that could play a
dynamic role throughout the healing process and the type of intravesicular cytokines
could determine the outcomes of wound healing.
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We were able to show a persistent increase in pro-inflammatory cytokines such as
IL-6, TNF, IL-8, IL-12, and INF-Ɣ in the VAC-treated wounds that could negatively
impact wound healing and render the wound to chronic state. These results are also
consistent with our clinical findings that showed overall healing rate is higher in the study
group subjects who have more EMVs. In contrast, Oasis Ultra Study Group EMVs have
fewer pro-inflammatory cytokines which have negative impact on healing. Alternatively,
pro-healing cytokines such as PDGF, bFGF, VEGF, and IL-1 R antagonist were found to
be elevated in the Oasis Ultra Study Group and could hasten the healing rate. Ultimately,
these findings suggest that intravesicular composition of EMVs could determine the
outcomes of the wound healing. However, there is a need to increase the number of
patients in the study that would provide more data to establish statistical significance.
The findings propose that a high demand on cytokines like PDGF, bFGF, VEGF,
IL-1, and IL6 are needed to start the healing response and as soon as the wound
progresses through phases of healing the demand of these cytokines decreased. These
findings are consistent with our clinical findings that showed higher healing rate in the
study group as compared with control group.
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The Role of Extracellular Microvesicles in Wound Healing
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Introduction: Extracellular Microvesicles (EMVs): EMVs are cellular membrane
fragments ranging from 100 nm to 1µm and are shed from almost all cell types. EMVs
mediate intercellular communication by transporting mRNA, miRNA, growth factors and
other proteins between cells. SIS (small intestinal submucosa) is a three layers of bio
absorbable extracellular matrix obtained from naturally derived, intact porcine small
intestinal sub-mucosa (SIS *). Objective: The aim of the study is to test correlation
between the EMVs concentration and the rate of wound healing in pressure wounds, to
analyze the EMV content, and to see whether the healing rate will be enhanced in SIS *
group. Material &Method: Wound fluid samples obtained from 12 patients with stage
IV trunk pressure ulcers. The patients were divided in two groups (6 in each group, n=6):
control group on negative pressure wound therapy (NPWT) alone & study group with
NPWT plus SIS dressing. EMVs were isolated using Ultracentrifugation method. EMVs
concentration was measured by Nanoparticle Tracking Analysis machine (Nano sight).
EMVs content was analyzed using 27 Bio-Plex Pro assay. Result: Using Statistical
software (SPSS), version13.00, simple linear regression was conducted to analyze our
data which showed there is a positive correlation between Extra cellular MVs
concentration and the rate of wound healing in both groups, study group, R= 0.87, R2 =
0.76 and P 0.05 and control group R = 0.78, R2 = 0.61and P 0.05. The overall healing rate
after 12 weeks of study was higher in the study group (87.3 %) in comparison with the
control group (56.3 %). Conclusion: Cellular communication through EMVs plays a
crucial role in wound healing. SIS * may enhance the cells' release of EMVs, which
provide damaged cells with required material to recover and hasten the healing rate.
* OASIS® Ultra, Smith and Nephew, St. Petersburg, FL.
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Extracellular Microvesicles as a Novel Biomarker for Wound Healing
Walid Mari. MD*, Sara Younes.MD, Jeffrey B. Travers, M.D., Ph. D David R. Cool,
Ph. D, Richard Simman, M.D., FACS, FACCWS.
Wright State University, Boonshoft School of Medicine, Department of
Pharmacology and Toxicology, Dayton, OH.
Background: Extracellular Microvesicles (EMVs): are cellular membrane fragments
ranging from 100 nm to 1µm and are shed from almost all cell types. EMVs mediate
intercellular communication by transporting mRNA, miRNA, growth factors and other
proteins between cells. SIS (small intestinal submucosa) is a three layers of bio absorbable
extracellular matrix obtained from naturally derived, intact porcine small intestinal submucosa (SIS *). Objective: To test the hypothesis that there is a correlation between the
concentration of EMVs and the percentage of wound healing in treated chronic wounds
and the healing percentage will be enhanced by the combination of Oasis ultra and NPWT.
Material &Method: Wound fluid samples obtained from 14 patients with stage IV trunk
pressure ulcers. The patients were divided in two groups (7 in each group, n=7): control
group treated with negative pressure wound therapy (NPWT) alone & study group treated
with NPWT and SIS dressing. EMVs were isolated using Ultracentrifugation method.
EMVs concentration was measured by Nanoparticle Tracking Analysis machine (Nano
sight). EMVs content was analyzed using 27 Bio-Plex Pro assay. Result & Conclusion:
The overall healing rate after 12 weeks of study was higher in the study group (89 %) in
comparison with the control group (52 %). There is a positive correlation between EMVs
concentration and the percentage of healing in both groups, R2 = 0.66, P ≤ 0.05. The control
group shows high level of intravesicular concentration of pro-inflammatory cytokines and
low pro-healing cytokines. However, study group shows high levels of intravesicular
concentration of pro-healing cytokines and low pro-inflammatory cytokines. This finding
suggests that the EMVs composition could determine the outcomes of the wound healing.
The EMVs particles in wound fluid could serve as potential biomarker of the wound
healing.
* OASIS® Ultra, Smith and Nephew, St. Petersburg, FL.
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